|
Christine G. Ocampo joined Avanir Pharmaceuticals in March of 2007 as the Corporate Controller. As Vice President of Finance, Ms. Ocampo is responsible for all accounting operations, budgeting, cash management, SEC reporting, and corporate compliance. During her tenure at Avanir Ms. Ocampo was an integral part of the successful divestiture of FazaClo� as well as leading the strategic consolidation of the corporate finance function.
Prior to joining the Company, Ms. Ocampo served as Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer and Secretary of Cardiogenesis Corporation from November 2003 until April 2006. From 2001 to November 2003, Ms. Ocampo served in the role of Vice President and Corporate Controller at Cardiogenesis. Prior to first joining Cardiogenesis in April 1997, Ms. Ocampo held a management position in Finance at Mills-Peninsula Health Systems in Burlingame, CA, and spent three years as an auditor for Ernst & Young LLP.
Ms. Ocampo graduated with a Bachelors of Science in Accounting from Seattle University and became a licensed Certified Public Accountant in 1996. | 